Ranbaxy gains approval for new manufacturing plant in Malaysia

India’s largest drugmaker Ranbaxy Laboratories (AB: BO) said yesterday that the government of Malaysia has given approval to the company for setting up a Greenfield manufacturing facility in Malaysia as an EPP (Entry Point Project) by its subsidiary Ranbaxy Malaysia Sdn Bhd.

Ranbaxy, which is 64% owned by Japan’s Daiichi Sankyo, will be investing around 125 million ringgit ($40 million) in this project that will provide employment to over 200 people. It will be Ranbaxy's second manufacturing facility in Malaysia.

Commenting on the approval Arun Sawhney, chief executive and managing director, Ranbaxy, said: "Ranbaxy has been providing high quality, affordable generic pharmaceuticals to the health care system of Malaysia for the last 30 years thereby helping the government to bring down health care costs. The setting up of a new manufacturing facility reinforces our commitment to the Malaysian market. In addition to serving the local market the facility will also export products to markets like ASEAN, Middle East, Europe, Sri Lanka, China and other select countries."

Will expand capacity to 3 billion doses a year